Business

Know the Business

Centene is the nation's largest government-sponsored managed care company, collecting $195B in premiums from Medicaid, Medicare PDP, and ACA Marketplace contracts and paying out 92 cents of every dollar in medical claims. The business runs on thin margins amplified by massive scale — operating income swings of 100 basis points on a $175B premium base move $1.7B of pretax profit. The market is underestimating how quickly CNC can normalize margins after the FY2025 goodwill impairment and Medicaid redetermination headwinds, and overestimating the permanence of elevated medical cost trends.

How This Business Actually Works

Centene's revenue engine is straightforward: state and federal governments pay fixed per-member-per-month (PMPM) premiums to manage healthcare for low-income and elderly populations. Centene then pays providers for the care those members consume.

Parser Error: syntax error at or near "union"

LINE 2: ....7 as hbr, 12.5 as members_m, 2025 as yr_sort order by yr_sort union all
                                                                          ^

LINE 2: ....7 as hbr, 12.5 as members_m, 2025 as yr_sort order by yr_sort union all
                                                                          ^

The profit mechanism: Centene earns the spread between PMPM premiums and medical costs (the Health Benefits Ratio, or HBR). Every 100bp improvement in HBR on $172B of premiums drops $1.7B to pretax income. SG&A runs at 7.4% — industry-best efficiency driven by scale — leaving operating margins in the 1-3% range in normal years.

Three things drive incremental profit: (1) rate adequacy — whether states raise PMPM rates fast enough to match medical cost inflation, (2) mix shift — Marketplace and PDP carry better margins than Medicaid, and (3) SG&A leverage — spreading fixed costs over a growing premium base.

The cost structure is almost entirely variable: 92% medical costs, 7.4% SG&A, leaving under 1% for everything else. This makes Centene a razor-thin margin business where execution on medical management, rate advocacy, and fraud prevention determines the difference between a great year and a disaster.

The Playing Field

The peer set reveals Centene's paradox: second-largest US health insurer by revenue ($195B) but valued at $26B — a fraction of UnitedHealth ($410B) despite being half its revenue size. The discount reflects three things. First, UNH earns diversified income through Optum (care delivery + PBM + analytics), while CNC is a pure managed care pass-through business. Second, CNC's government-heavy mix (57% Medicaid) carries lower margins than commercial insurance. Third, the FY2025 goodwill impairment and Medicaid margin pressure have cratered investor confidence.

Molina is the closest comp — also Medicaid-focused, similar SG&A efficiency — and trades at 15x earnings vs CNC's ~25x on depressed FY2025 adjusted earnings. If CNC normalizes to guidance ($3.40+ EPS in FY2026), the forward P/E compresses to ~16x, roughly in line with Molina.

Is This Business Cyclical?

Managed Medicaid is countercyclical by design — enrollment rises during recessions as more people qualify for government assistance. Centene's Medicaid membership grew from 4.4M in 2010 to a peak of 15.7M post-COVID (2023), then dropped to 12.5M through redeterminations.

The real cycle hits through three channels:

Rate lag. Medical costs rise immediately; state Medicaid rate increases arrive 6-18 months later. FY2025's HBR of 91.9% vs FY2024's 88.3% captures this lag — behavioral health, home health, and specialty pharmacy costs surged while rates were still catching up. Composite rates closed FY2025 at +5.5%, and management expects mid-4% for FY2026.

Membership churn. Post-COVID redeterminations stripped 3.2M Medicaid members from CNC between March 2023 and December 2025. The OBBBA (July 2025) adds work requirements and more frequent eligibility checks, likely shedding additional lower-acuity members and raising per-member morbidity.

Regulatory whiplash. Enhanced APTCs expired end of 2025, expected to shrink Marketplace enrollment from 5.5M to ~3.5M in Q1 2026 (already tracking to 3.58M). CNC repriced 95% of Marketplace membership in Q3 2025 to compensate.

The business survived every cycle test: revenue never declined year-over-year even as operating income fluctuated dramatically. The FY2025 GAAP loss (-$6.7B) was entirely driven by a non-cash $6.7B goodwill impairment — adjusted operating income was positive.

The Metrics That Actually Matter

HBR is the only metric that matters for quarters. A 50bp HBR improvement on $172B of premiums adds $860M pretax. Q1 FY2026 HBR of 87.3% is 360bp better than FY2025's 91.9%, signaling aggressive margin recovery. Medicaid HBR improved to 93.1% (down 50bp YoY) — third consecutive quarter of progress.

SG&A ratio is the structural advantage. At 7.4%, CNC runs leaner than UNH (13.3%), ELV (11.2%), and HUM (11.8%). Only Molina (7.2%) matches it. This efficiency comes from scale: spreading fixed costs over $175B of premium revenue.

Adjusted EPS strips the signal from the noise. GAAP EPS of -$13.53 in FY2025 is meaningless for valuation — it's the $6.7B goodwill impairment. Adjusted EPS of $2.08 shows the underlying business still earned money. The Q1 FY2026 beat ($3.37 vs internal expectations) and raised full-year guidance (over $3.40) suggest FY2026 adjusted EPS could approach $6-7.

What I'd Tell a Young Analyst

Watch three things: Medicaid HBR trajectory quarter by quarter (must keep improving toward 90%), Marketplace membership retention post-APTC expiration (3.5M is the floor the company priced for), and whether the Q1 FY2026 earnings beat ($3.37, nearly $0.50 above internal expectations) is the start of a multi-quarter beat cycle or a one-off from favorable flu season timing.

The market treats CNC like a broken company because of the $6.7B goodwill impairment headline and the FY2025 GAAP loss. But the impairment was non-cash and reflected overpayment for WellCare in 2020, not deterioration of the core Medicaid franchise. Adjusted operating cash flow was $5.1B in FY2025 — the business generates real cash.

The biggest risk is not medical costs — those are cyclical and rates eventually catch up. The risk is political: the OBBBA's Medicaid work requirements and provider tax changes (effective 2028) could structurally shrink the Medicaid managed care TAM. If Congress cuts Medicaid funding faster than CNC can shift members to Medicare D-SNPs and Marketplace, the growth engine stalls. That transition — from Medicaid-first to multi-product — is the strategic bet Sarah London is making with the new leadership structure (Dan Finke for Medicaid/Commercial, Michael Carson for Medicare/Specialty).